NeuroSense Therapeutics Warrant
NRSNW
5 hedge funds and large institutions have $109K invested in NeuroSense Therapeutics Warrant in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, reducing their positions, and closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
4.12% more ownership
Funds ownership: 0% → 4.12% (+4.1%)
52% less capital invested
Capital invested by funds: $229K → $109K (-$120K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$1.24K |
| 2 |
CS
Clear Street
New York
|
+$1.04K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$506 |
Top Sellers
NRSNW Hedge Fund Activity: Q3 2022 in Review
5 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q3 2022, worth a combined $109K — down 52% from $229K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new NRSNW positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Warberg Asset Management, adding an estimated $1.24K.
- 5 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q3 2022, up from 4 in Q2 2022.
- Funds reported $109K of NeuroSense Therapeutics Warrant stock for Q3 2022, down 52% quarter-over-quarter.
- 1 fund opened new NeuroSense Therapeutics Warrant positions in Q3 2022 and 0 closed out, a net change of +1 holder.
- The largest NeuroSense Therapeutics Warrant buyer in Q3 2022 was Warberg Asset Management, an estimated $1.24K added.
Based on aggregated 13F filings for Q3 2022.